TradeUP (NASDAQ:UPTD) announced in an 8-K this morning that its shareholders approved its combination with Estrella Biopharma at a special meeting yesterday, July 31.
650,580 shares were redeemed in connection with the vote, leaving the SPAC with just 98,074 public shares remaining from its original IPO. Should these results stand, TradeUp will have finished its process with 94.8% of shares redeemed.
In addition to its roughly $1 million in remaining trust capital, the SPAC also secured a $6.8 million PIPE last week. This effectively allowed Estrella lender Eureka Therapeutics to convert about $6.8 million in debts into equity in the form of 680,000 units, each containing one common share and one preferred share.
But, this is still short of the deal’s minimum cash condition, which requires TradeUp to maintain $20 million in cash available unless waived. The SPAC secured a one-year extension to its transaction deadline last month, however, so it has time to make additional moves to shore up this cash situation.
Should the deal go to close as is, these PIPE shares are to be locked up for one year, so they would not ease the low-float scenario that would face Estrella at close. Perhaps in anticipation of this, TradeUp stock spiked up to about +77% in pre-market trading at one point this morning.
What is likely to have an impact is the common stock purchase agreement TradeUp signed with White Lion Capital in April. Under this agreement, White Lion is to purchase up to $50 million in shares in the combined company after close. The maximum investment for agreement would appear to be unavailable even if White Lion may purchase shares recently tendered for redemption.
But, White Lion will nonetheless be issued 250,000 shares shortly after close in return for having made its commitments, which would more than triple Estrella’s liquid public share count.
TradeUp initially announced its $398 million combination with Estrella Biopharma in October 2022. Emeryville, California-based Estrella is developing three potential cancer therapies aimed at improving the effectiveness of T-cell treatments.
K&F Growth Acquisition Corp. II (NASDAQ:KFIIU) announced the pricing of its $250 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “KFIIU”, Wednesday, February 5, 2025. The new SPAC intends to combine with a target company in the experiential entertainment industry underpinned by strong secular growth, a skilled...
Rithm Acquisition Corp. (NYSE:RAC.U) has filed for a $200 million SPAC with a loaded room of underwriters to hunt down a target in financial services or real estate. The Rithm team has driven aggressive terms for the sponsor’s first SPAC with the help of a deep-pocketed backer and the trio of Citigroup, BTIG and USB...
At the SPAC of Dawn With the North American tariff threats set aside for now, there’s still plenty of momentum for the sorts of investments that might be able to dodge such trade disputes, or become more valuable should trade barriers arise. Among the clearest examples of these are producers of critical materials like rare...
In January 2025, SPAC teams continued extending beyond their third round, with one SPAC notably reaching its seventh extension vote as they searched for suitable deals. The month saw five announcements, marking the highest level in recent months, while only four SPACs held completion votes. Extension Votes In January, 14 extension votes were scheduled, representing...
At the SPAC of Dawn February is set to start with the jolt of a new potential trade war in North America. While some observers had expected tough trade action on China, the incoming administration’s decision to begin with 25% tariffs on the US’ biggest trading partners and neighbors, Mexico and Canada, and tariffs of...